Insider Transactions in Q1 2024 at Eagle Pharmaceuticals, Inc. (EGRX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2024
|
Scott Tarriff |
SELL
Payment of exercise price or tax liability
|
Direct |
2,119
-0.46%
|
$12,714
$6.27 P/Share
|
|
Feb 27
2024
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,589
-3.21%
|
$9,534
$6.44 P/Share
|
|
Feb 27
2024
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,800
+7.12%
|
-
|
|
Feb 27
2024
|
Scott Tarriff |
SELL
Payment of exercise price or tax liability
|
Direct |
3,154
-0.68%
|
$18,924
$6.44 P/Share
|
|
Feb 27
2024
|
Scott Tarriff |
BUY
Grant, award, or other acquisition
|
Direct |
12,950
+2.7%
|
-
|
|
Feb 02
2024
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
934
-2.0%
|
$4,670
$5.85 P/Share
|
|
Jan 05
2024
|
Scott Tarriff |
SELL
Payment of exercise price or tax liability
|
Direct |
4,322
-0.79%
|
$21,610
$5.13 P/Share
|
|
Jan 05
2024
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
735
-1.55%
|
$3,675
$5.13 P/Share
|